Allergan Inc. chalked up a third FDA complete response letter (CRL) regarding Semprana (dihydroergotamine), the orally inhaled acute migraine treatment formerly known as Levadex, and the heart of its $958 million acquisition of MAP Pharmaceuticals Inc. Read More
Shareholders in Nordic Nanovector AS voted Friday to approve an NOK250 million (US$40.6 million) private placement and to raise the offering by a further NOK50 million, evidence that Bayer AG's recently closed $2.9 billion buyout of radiopharmaceutical developer Algeta ASA has had a positive impact on investor sentiment in Norway. Read More
LONDON – The scandal surrounding Glaxosmithkline plc (GSK) in China moved up a notch, with the revelation that a secretly filmed sex video of the former head of business there, Mark Reilly, was sent to senior executives, including CEO Andrew Witty, in an apparent attempt at blackmail. Read More
The final day of the second quarter ended with two more European biotechs filing for proposed initial public offerings (IPOs), both taking advantage of the emerging growth provision under the JOBS Act to pick up a U.S. public listing and pad their balance sheets. Read More
TOKYO – Japan's Taiho Oncology Inc. reported positive results from a global phase III trial of its oral combination anticancer drug TAS-102 (trifluridine and tipiracil hydrochloride) in refractory metastatic colorectal cancer (mCRC). Read More
A free agent after last July's $704 million buyout of Trius Therapeutics Inc., former CEO Jeffrey Stein was "approached with numerous opportunities" before choosing the earliest-stage prospect and "by far the most exciting one" in antifungals start-up Cidara Therapeutics Inc., he said. Read More
Heron Therapeutics Inc., of Redwood City, Calif., closed its underwritten public offering of 4,751,358 shares of common stock at a price of $11.75 per share. Read More
Alimera Sciences Inc., of Atlanta, reported a positive outcome of the repeat-use procedure for Iluvien for the treatment of chronic diabetic macular edema (DME) in an additional 10 European Union countries – Ireland, the Netherlands, Belgium, Luxembourg, Sweden, Denmark, Finland, Norway, Poland and the Czech Republic. Read More
Brickell Biotech Inc., of Miami, entered into a license agreement with Merz North America Inc., granting Merz, of Greensboro, N.C., an exclusive North American license, with certain additional international rights, to develop and commercialize a retinoid compound, BBI-3000, for the treatment of skin conditions known to be responsive to retinoid agents, such as acne and psoriasis. Read More
Eisai Ltd., of Hatfield, UK, part of Eisai Co. Ltd., reported results of an interim analysis of the non-interventional EPOS (Eslicarbazepine acetate in Partial-Onset Seizure) study presented this week at the XXI European Congress on Epileptology in Stockholm, showing that once-daily Zebinix (eslicarbazepine acetate) retained seizure control and is well tolerated when given as an add-on to anti-epileptic monotherapy to adults in routine clinical practice. Read More
PTC Therapeutics Inc., of South Plainfield, N.J. started a global confirmatory phase III trial of its investigational new drug Translarna (ataluren) in patients with nonsense mutation cystic fibrosis. Read More
